<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03443804</url>
  </required_header>
  <id_info>
    <org_study_id>DW1401-302</org_study_id>
    <nct_id>NCT03443804</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients</brief_title>
  <acronym>2</acronym>
  <official_title>A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase 3 Clinical Trial to Evaluated the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the Efficacy and Safety of DW1401 versus Stillen tab. in Patients with Acute or&#xD;
      Chronic Gastritis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy rate on gastroscopy</measure>
    <time_frame>0, week 2</time_frame>
    <description>The efficacy rate is obtained from the following formula using the subject whose erroneous score is improved by 50% or more as compared with before the study drug administration.&#xD;
The efficacy rate(%) = (number of effective cases)/(all cases) x 100&#xD;
Effective case is determined by the grade change of erosion. A case in which the grade changes from 4 to 2 or 1, from 3 to 1, or from 2 to 1 is judged as an effective case.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rate on gastroscopy</measure>
    <time_frame>0, week 2</time_frame>
    <description>Judging from the gastroscopic examination as normal (no erosion), the cure rate is obtained as follows.&#xD;
Cure rate(%) = (number of cures(no erosion))/(all cases) x 100</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">462</enrollment>
  <condition>Gastritis Acute</condition>
  <condition>Gastritis Chronic</condition>
  <arm_group>
    <arm_group_label>Test(DW1401)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tid PO, DW1401+Placebo of Stillen tab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference(Stillen tab.)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tid PO, Stillen tab.+Placebo of DW1401</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test(DW1401)</intervention_name>
    <description>DW1401+Placebo of Stillen tab.</description>
    <arm_group_label>Test(DW1401)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference(Stillen tab.)</intervention_name>
    <description>Stillen tab.+Placebo of DW1401</description>
    <arm_group_label>Reference(Stillen tab.)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who were diagnosed with acute or chronic gastritis in a gastroscopy performed&#xD;
             within 7 days prior to administration of this trial.&#xD;
&#xD;
          -  At least one or more erosions have been identified on gastroscopy.&#xD;
&#xD;
          -  Patients who decided to voluntarily participate in this trial and agreed in writing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who can not undergo gastroscopy&#xD;
&#xD;
          -  Peptic ulcer (except scarring) and reflux esophagitis&#xD;
&#xD;
          -  Patients who have had gastric acid suppression surgery or stomach/esophagus surgery&#xD;
             (except for simple perforation surgery and appendectomy)&#xD;
&#xD;
          -  Patients with a history of gastrointestinal malignancies&#xD;
&#xD;
          -  Zollinger-Ellison syndrome patients&#xD;
&#xD;
          -  Patient with spontaneous coagulation disorder&#xD;
&#xD;
          -  Patients with an allergic or hypersensitive response to a study drug&#xD;
&#xD;
          -  Patients with a potential pregnancy.&#xD;
&#xD;
          -  Patients who had clinically significant abnormalities in the screening test. (ALT,&#xD;
             AST, BUN, Serum creatinine is more than twice the upper limit)&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Those currently taking other study drugs&#xD;
&#xD;
          -  patients who were judged to be ineligible for the trial by the principle investigator&#xD;
             and the person in charge.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 11, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan for IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

